Skip to main content

Table 3 Baseline values and changes in efficacy parameters

From: Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

Parameter Baseline Week 12 Week 24
Glandular function tests    
   Schirmer's test (millimeters per 5 minutes) 2.0 ± 3.2 3.4 ± 3.5 4.4 ± 4.9
   Whole saliva (grams per 5 minutes) 0.49 ± 0.41 0.48 ± 0.41 0.56 ± 0.41
Laboratory tests    
   Erythrocyte sedimentation rate (mm/hour) 47.6 ± 20.5 44.1 ± 23.3 44.2 ± 21.0
   Gamma globulins (g/L) 21.3 ± 6.3 19.5 ± 8.6a 18.8 ± 7.5b
   IgG (mg/dL) 2,159 ± 949 2,048 ± 755 2,025 ± 895
   IgM (mg/dL) 189 ± 108 144 ± 62.7a 142 ± 62.8a
   IgA (mg/dL) 399 ± 417 359 ± 363 329 ± 305
   Rheumatoid factor IgM (IU/mL) 275 ± 504 193 ± 380 179 ± 317a
   Anti-SSA antibodies (U/mL) 5,863 ± 5,321 6,308 ± 4,008 5,892 ± 8,859
   Anti-SSB antibodies (U/mL) 1,217 ± 1,386 1,424 ± 1,925 1,320 ± 1,668
   C3 (mg/dL) 99.3 ± 30.2 101 ± 33.5 108 ± 34.7b
   C4 (mg/dL) 14.9 ± 8.8 16.4 ± 9.5a 16.8 ± 8.9b
Subjective findings    
   VAS sicca syndrome (0 to 100 mm) 68.7 ± 15.6 56.4 ± 19.9 52.8 ± 20.8a
   VAS arthralgia (0 to 100 mm) 62.1 ± 23.4 45.1 ± 34.3 47.5 ± 30.0
   VAS fatigue (0 to 100 mm) 63.4 ± 24.0 57.4 ± 33.4 65.3 ± 22.6
   Use of artificial teardrops (times per day) 3.7 ± 2.3 1.8 ± 1.3a 1.6 ± 1.9b
   Health Assessment Questionnaire score 0.73 ± 0.77 0.81 ± 0.84 0.73 ± 0.80
  1. ap < 0.05 versus baseline value analyzed by Wilcoxon signed rank test; bp < 0.02 versus baseline value analyzed by Wilcoxon signed rank test. Table presents outcome parameters in the eight patients with primary Sjögren syndrome who completed the study. Data are presented as mean ± standard deviation. Ig, immunoglobulin; VAS, visual analogue scale.